Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial

被引：9
|
作者：
Chi, Y. [1 ]
Gao, M. [2 ]
Zhang, Y. [3 ]
Shi, F. [4 ]
Cheng, Y. [5 ]
Guo, Z. [6 ]
Ge, M. [7 ]
Qin, J. [8 ]
Zhang, J. [9 ]
Li, Z. [10 ]
Zhou, X. [11 ]
Huang, R. [12 ]
Chen, X. [13 ]
Liu, H. [14 ]
Cheng, R. [15 ]
Xu, Z. [16 ]
Zheng, X. [2 ]
Li, D. [2 ]
Tang, P. [17 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Clin Res Ctr Canc, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Thyroid & Neck Oncol, Tianjins Clin Res Ctr Canc, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjin, Peoples R China
[3] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Head & Neck Surg Dept,Jiangsu Canc Hosp, Nanjing, Peoples R China
[4] Hunan Canc Hosp, Nucl Med Ctr, Thyroid Tumour Internal Med Dept, Changsha, Peoples R China
[5] Jilin Canc Hosp, Dept Med Oncol, Changchun, Jilin, Peoples R China
[6] Sun Yat Sen Univ, Ctr Canc, Head & Neck Surg, Guangzhou, Peoples R China
[7] Chinese Acad Sci, Head & Neck Surg Inst Canc & Basic Med ICBM, Canc Hosp,Univ Chinese Acad Sci,Zhejiang Canc Hos, Zhejiang Prov Peoples Hosp,Peoples Hosp,Hangzhou, Hangzhou, Peoples R China
[8] Zhengzhou Univ, Affiliated Canc Hosp, Thyroid & Head & Neck Surg, Henan Canc Hosp, Zhengzhou, Peoples R China
[9] Harbin Med Univ, Canc Hosp, Thyroid Surg Ward, Harbin, Peoples R China
[10] China Med Univ, Liaoning Tumor Hosp & Inst, Tumor Hosp, Dept Head & Neck Surg, Shenyang, Peoples R China
[11] Chongqing Univ, Canc Hosp, Chongqing Canc Hosp, Head & Neck Surg, Chongqing, Peoples R China
[12] Sichuan Univ, West China Hosp, Nucl Med, Chengdu, Peoples R China
[13] Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China
[14] Fujian Canc Hosp, Head & Neck Dept, Fuzhou, Peoples R China
[15] Kunming Med Univ, Affiliated Hosp 1, Dept Thyroid Surg, Kunming, Yunnan, Peoples R China
[16] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Head & Neck Surg,Natl Canc Ctr, Beijing, Peoples R China
[17] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept VIP,Natl Canc Ctr, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA88
引用
收藏
页码：S1215 / S1215
页数：1
相关论文
共 50 条
  • [41] MANAGEMENT OF ADVERSE EVENTS ASSOCIATED WITH CABOZANTINIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA, HEPATOCELLULAR CARCINOMA, OR RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
    Lee-Ramos, Steven
    Seery, Virginia
    Andresen, Diane
    Hall, Tasha
    Berry, Nicholas
    Martone, Brenda
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [42] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Maghsoomi, Zohreh
    Emami, Zahra
    Malboosbaf, Ramin
    Malek, Mojtaba
    Khamseh, Mohammad E.
    BMC CANCER, 2021, 21 (01)
  • [43] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Zohreh Maghsoomi
    Zahra Emami
    Ramin Malboosbaf
    Mojtaba Malek
    Mohammad E. Khamseh
    BMC Cancer, 21
  • [44] A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
    Lim, S. M.
    Chang, H.
    Yoon, M. J.
    Hong, Y. K.
    Kim, H.
    Chung, W. Y.
    Park, C. S.
    Nam, K. H.
    Kang, S. W.
    Kim, M. K.
    Kim, S. B.
    Lee, S. H.
    Kim, H. G.
    Na, I. I.
    Kim, Y. S.
    Choi, M. Y.
    Kim, J. G.
    Park, K. U.
    Yun, H. J.
    Kim, J. H.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 3089 - 3094
  • [45] Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer
    Buzdar, A
    O'Shaughnessy, JA
    Booser, DJ
    Pippen, JE
    Jones, SE
    Munster, PN
    Peterson, P
    Melemed, AS
    Winer, E
    Hudis, C
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) : 1007 - 1014
  • [46] An exploratory phase II clinical trial of apatinib in progressive radioiodine refractory differentiated thyroid cancer
    Lin, Yan-Song
    Zhang, Xin
    Liu, Yanqing
    Wang, Chen
    Zhang, Teng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Phase III double-blind trial of Arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer
    Deshmane, VijayaLaxmi
    Krishnamurthy, S.
    Melemed, Allen S.
    Peterson, Patrick
    Buzdar, Aman U.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (31) : 4967 - 4973
  • [48] OUTCOMES BY SITE OF METASTASIS FOR PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER TREATED WITH LENVATINIB VERSUS PLACEBO: RESULTS FROM A PHASE 3, RANDOMIZED TRIAL
    Young, Louise
    Habra, Mouhammed
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 134 - 134
  • [49] Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial
    Haugen, B.
    French, J. D.
    Worden, F.
    Konda, B.
    Sherman, E. J.
    Dadu, R.
    Gianoukakis, A. G.
    Mccue, S.
    Foster, N.
    Bowles, D. W.
    Wirth, L. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1086 - S1087
  • [50] Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC)
    Sehgal, Kartik
    Shi, Ruichao
    Pappa, Theodora
    Min, Judy K.
    Oakley, Liam B.
    ONeill, Anne
    Dennis, Michael J.
    Deshpande, Hari Anant
    Haddad, Robert I.
    Lorch, Jochen H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345